{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:39:22Z","timestamp":1789778362310,"version":"4.0.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"vor","delay-in-days":406,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"W.L. Gore and Associates, Inc"},{"name":"W.L.\u00a0Gore and Associates, Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jcin.2014.01.169","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T15:48:00Z","timestamp":1408376880000},"page":"905-912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Results of the U.S. Food and Drug Administration Continued Access Clinical Trial of the GORE HELEX Septal Occluder for Secundum Atrial Septal Defect"],"prefix":"10.1016","volume":"7","author":[{"given":"Alexander J.","family":"Javois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Rome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M.","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo H.","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Latson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.jcin.2014.01.169_bib1","first-page":"498A","article-title":"Acute and long-term follow-up results with the Helex Septal Occluder in an animal model","volume":"35","author":"Zahn","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2014.01.169_bib2","first-page":"268","article-title":"Helex Septal Occluder for closure of atrial septal defects","volume":"2","author":"Latson","year":"2000","journal-title":"Curr Interv Cardiol Rep"},{"key":"10.1016\/j.jcin.2014.01.169_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/hc3301.092792","article-title":"Development and testing of the Helex septal occluder, a new expanded polytetrafluoroethylene atrial septal defect occlusion system","volume":"104","author":"Zahn","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2014.01.169_bib4","first-page":"941","article-title":"Fracture of the GORE HELEX septal occluder: associated factors and clinical outcomes","volume":"73","author":"Fagan","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2014.01.169_bib5","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.jacc.2006.11.053","article-title":"Results of the U.S. Multicenter Pivotal Study of the HELEX Septal Occluder for percutaneous closure of secundum atrial septal defects","volume":"49","author":"Jones","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2014.01.169_bib6","first-page":"104","article-title":"Analysis of US FDA HELEX trial data: how the addition of hydrophilic coating to the ePTFE has affected enrollment and outcome","volume":"66","author":"Javois","year":"2005","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2014.01.169_bib7","doi-asserted-by":"crossref","first-page":"1129.e7","DOI":"10.1016\/j.ahj.2006.01.005","article-title":"Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX Septal Occluder","volume":"151","author":"Latson","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2014.01.169_bib8","first-page":"777","article-title":"Partial prolapse of a HELEX device associated with early\u00a0frame fracture and mitral valve perforation","volume":"74","author":"Qureshi","year":"2009","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879814008413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879814008413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:59:59Z","timestamp":1761847199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879814008413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1936879814008413"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2014.01.169","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of the U.S. Food and Drug Administration Continued Access Clinical Trial of the GORE HELEX Septal Occluder for Secundum Atrial Septal Defect","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2014.01.169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}